AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19120336 — intervention group
Group type: COMPARATOR
Intervention: Formulations with higher fat content (not specified)
Number of subjects: 0
Study 17538086 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenous weekly)
Number of subjects: 626
Study 17538086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (15 mg temsirolimus weekly + 6 million U interferon alfa three times weekly)
Number of subjects: 626
Study 17538086 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (3 million U subcutaneously three times weekly, increasing to 18 million U)
Number of subjects: 626
Study 14742392 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous ephedrine
Number of subjects: 390
Study 15598111 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit social comparisons
Number of subjects: 0
Study 15598111 — intervention group
Group type: COMPARATOR
Intervention: Implicit social comparisons
Number of subjects: 0
Study 10360849 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg/15 min followed by 0.4 mg/h) + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Number of subjects: 25
Study 10360849 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Number of subjects: 25
Study 10360849 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 25
Study 7560572 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent povidone-iodine
Number of subjects: 120
Study 7560572 — intervention group
Group type: COMPARATOR
Intervention: 0.2 percent chlorhexidine
Number of subjects: 120
Study 7560572 — intervention group
Group type: COMPARATOR
Intervention: sterile water
Number of subjects: 120
Study 1787282 — intervention group
Group type: EXPERIMENTAL
Intervention: Khitchri and half-strength cow's milk formula after initial rehydration with ORS (group B)
Number of subjects: 69
Study 1787282 — intervention group
Group type: COMPARATOR
Intervention: WHO ORS alone for the first 24 hours followed by khitchri and half-strength cow's milk formula (group A)
Number of subjects: 69
Study 6125164 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (1 mg i.v.)
Number of subjects: 10
Study 6125164 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol (1 mg i.v.)
Number of subjects: 10
Study 6125164 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (1 mg i.v.)
Number of subjects: 10
Study 30654644 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine plus cognitive remediation and social skills training
Number of subjects: 28
Study 30654644 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cognitive remediation and social skills training
Number of subjects: 28
Study 29383569 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam extended-release (ER) tablets
Number of subjects: 34
Study 29383569 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam ER tablets with food
Number of subjects: 34
Study 29383569 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam immediate-release (IR) tablets
Number of subjects: 34
Study 27390949 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 8029
Study 27390949 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 8029
Study 24897906 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual modality training condition
Number of subjects: 175
Study 24897906 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual modality condition
Number of subjects: 175
Study 24897906 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory modality condition
Number of subjects: 175
Study 24897906 — intervention group
Group type: COMPARATOR
Intervention: No-training condition
Number of subjects: 175
Study 24897906 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual condition with rehearsal
Number of subjects: 175
Study 22554213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led psycho-education program
Number of subjects: 79
Study 22554213 — intervention group
Group type: COMPARATOR
Intervention: Usual psychiatric outpatient care
Number of subjects: 79
Study 20181806 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 39
Study 20181806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oils (4 g/d)
Number of subjects: 39
Study 20181806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Atorvastatin + Fish oils)
Number of subjects: 39
Study 20181806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18157417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical aorto-saphenous anastomosis
Number of subjects: 12
Study 18157417 — intervention group
Group type: COMPARATOR
Intervention: Conventional anastomosis
Number of subjects: 12
Study 16046530 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell depletion (TCD) plus cyclosporine (CSA)
Number of subjects: 404
Study 16046530 — intervention group
Group type: COMPARATOR
Intervention: Unmodified grafts with CSA plus methotrexate (M/C)
Number of subjects: 404
Study 16046530 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell depletion (TCD)
Number of subjects: 404
Study 12354684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch cue (thinking about what they had eaten for lunch)
Number of subjects: 0
Study 12354684 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch today cue
Number of subjects: 0
Study 12354684 — intervention group
Group type: COMPARATOR
Intervention: No cue (free thought condition)
Number of subjects: 0
Study 12354684 — intervention group
Group type: COMPARATOR
Intervention: Lunch yesterday cue
Number of subjects: 0
Study 10077348 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 0
Study 10077348 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine administration
Number of subjects: 0
Study 10077348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GH and triiodothyronine
Number of subjects: 0
Study 10077348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7554199 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment group
Number of subjects: 516
Study 7554199 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 516
Study 31519475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 13
Study 31519475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (40 mg)
Number of subjects: 13
Study 31519475 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam and Stiripentol
Number of subjects: 13
Study 31519475 — intervention group
Group type: COMPARATOR
Intervention: Clobazam
Number of subjects: 13
Study 28410510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet application after local forearm warming (active warming group; n=36)
Number of subjects: 72
Study 28410510 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet application alone (passive warming group; n=36)
Number of subjects: 72
Study 26568899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 207
Study 26568899 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Education and Support
Number of subjects: 207
Study 23860421 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible pylon system
Number of subjects: 28
Study 21224820 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated ECC-set (group A)
Number of subjects: 63
Study 21224820 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC-set (group B)
Number of subjects: 63
Study 21224820 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC-set (group C)
Number of subjects: 63
Study 21224820 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 63
Study 19499468 — intervention group
Group type: EXPERIMENTAL
Intervention: King LT
Number of subjects: 27
Study 19499468 — intervention group
Group type: COMPARATOR
Intervention: Combitube
Number of subjects: 27
Study 16995587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ACTH test (LDT)
Number of subjects: 30
Study 16995587 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ACTH test (SDT)
Number of subjects: 30
Study 16995587 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 μg or 600 μg daily doses)
Number of subjects: 30
Study 16995587 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary free cortisol excretion
Number of subjects: 30
Study 14758580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 44
Study 14758580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 11240872 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% halothane
Number of subjects: 21
Study 11240872 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 21
Study 9292541 — intervention group
Group type: EXPERIMENTAL
Intervention: RheothRx (poloxamer 188) Injection
Number of subjects: 50
Study 9292541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8038025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at a target heart rate of 100 beats/min
Number of subjects: 6
Study 8038025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at a target heart rate of 150 beats/min
Number of subjects: 6
Study 8038025 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of atropine (target heart rate 100 beats/min)
Number of subjects: 6
Study 8038025 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional infusion of adrenaline and noradrenaline
Number of subjects: 6
Study 8038025 — intervention group
Group type: COMPARATOR
Intervention: Control state without cycling
Number of subjects: 6
Study 3524645 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (both intravenous and oral)
Number of subjects: 17
Study 3524645 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 17
Study 30590590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2702
Study 28279428 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (2850 IE anti‐Xa=0.3ml daily subcutaneous self-injection)
Number of subjects: 467
Study 28279428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5mg=0.5ml daily subcutaneous self-injection)
Number of subjects: 467
Study 28279428 — intervention group
Group type: COMPARATOR
Intervention: Control (no thromboprophylaxis)
Number of subjects: 467
Study 25991154 — intervention group
Group type: EXPERIMENTAL
Intervention: Telekit telehealth system
Number of subjects: 60
Study 23469888 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg single oral dose of memantine
Number of subjects: 0
Study 23469888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21255399 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-skills training and parental training plus standard treatment
Number of subjects: 52
Study 21255399 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 52
Study 19150264 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17062805 — intervention group
Group type: EXPERIMENTAL
Intervention: MedGem (MG)
Number of subjects: 100
Study 17062805 — intervention group
Group type: COMPARATOR
Intervention: Delta Trac II (DT)
Number of subjects: 100
Study 17062805 — intervention group
Group type: EXPERIMENTAL
Intervention: MedGem (MG) sitting position
Number of subjects: 100
Study 17062805 — intervention group
Group type: EXPERIMENTAL
Intervention: MedGem (MG) supine position
Number of subjects: 100
Study 12975635 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) consumption
Number of subjects: 19
Study 12975635 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) consumption
Number of subjects: 19
Study 10935781 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin(GIK)
Number of subjects: 28
Study 10935781 — intervention group
Group type: COMPARATOR
Intervention: alpha-ketoglutarate enrichment of blood cardioplegia
Number of subjects: 28
Study 8967706 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1000 mg/d) and vitamin D3 (500 IU/d)
Number of subjects: 96
Study 8967706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 8967706 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3
Number of subjects: 96
Study 1390144 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (150 mg b.i.d. orally)
Number of subjects: 72
Study 1390144 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (2.5 MU x 8 daily intravenously, then 6 MU daily orally)
Number of subjects: 72
Study 1390144 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (control group)
Number of subjects: 72
Study 2983909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naloxone (5.4 mg/h)
Number of subjects: 13
Study 2983909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naloxone (0.8 mg/h)
Number of subjects: 13
Study 2983909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31843269 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-TDV
Number of subjects: 351
Study 31843269 — intervention group
Group type: EXPERIMENTAL
Intervention: TDV
Number of subjects: 351
Study 29741749 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario, simulation, and debriefing
Number of subjects: 60
Study 29741749 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario and simulation
Number of subjects: 60
Study 29741749 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario
Number of subjects: 60
Study 28060463 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Activity Intervention (PAI)
Number of subjects: 29
Study 28060463 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 29
Study 26673919 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive cognitive‐motor training (ICMT) - four stepping games, three 20-minute sessions per week for 16 weeks
Number of subjects: 90
Study 26673919 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - received an evidence‐based brochure on fall prevention
Number of subjects: 90
Study 26673919 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adherers to ICMT
Number of subjects: 90
Study 26673919 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherers to ICMT
Number of subjects: 90
Study 23302973 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous etanercept 50 mg administered 90 minutes before surgery
Number of subjects: 77
Study 23302973 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 77
Study 23302973 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pain at 1 month
Number of subjects: 77
Study 21679463 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus the REACT intervention
Number of subjects: 0
Study 21679463 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0
Study 18164672 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment (4.5 IU intramuscularly daily for 4 weeks)
Number of subjects: 114
Study 18164672 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 114
Study 18164672 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 114
Study 16505196 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial blood pressure measurement
Number of subjects: 484
Study 16505196 — intervention group
Group type: COMPARATOR
Intervention: Carotid augmentation index
Number of subjects: 484
Study 16505196 — intervention group
Group type: COMPARATOR
Intervention: Systemic arterial compliance
Number of subjects: 484
Study 15243933 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 909 (oral attenuated typhoid vaccine) at doses of 10(6-9) cfu
Number of subjects: 32
Study 11377309 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 3040
Study 11377309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 10211027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat 0.02 mg kg‐1
Number of subjects: 213
Study 10211027 — intervention group
Group type: COMPARATOR
Intervention: Control (5% glucose 0.02 ml kg‐1)
Number of subjects: 213
Study 7943305 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rhGH (0.15 mg somatotropin · kg‐1 · day‐1) intramuscular injections
Number of subjects: 20
Study 7943305 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with daily rhGH
Number of subjects: 20
Study 7943305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 20
Study 3058105 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (CSP)
Number of subjects: 0
Study 3058105 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 31419155 — intervention group
Group type: EXPERIMENTAL
Intervention: Verb Network Strengthening Treatment (VNeST), 15 hours of therapy delivered by experienced speech-language pathologists.
Number of subjects: 56
Study 31419155 — intervention group
Group type: COMPARATOR
Intervention: Intensive therapy (as part of the study condition).
Number of subjects: 56
Study 31419155 — intervention group
Group type: COMPARATOR
Intervention: Distributed therapy (as part of the study condition).
Number of subjects: 56
Study 29947051 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based randomized clinical trials
Number of subjects: 0
Study 29947051 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical trials
Number of subjects: 0
Study 25905441 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid genetic counseling and testing (RGCT)
Number of subjects: 265
Study 25905441 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 265
Study 24595305 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX) during energy deficit
Number of subjects: 15
Study 24595305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 15 g of whey protein after REX in ED
Number of subjects: 15
Study 24595305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 30 g of whey protein after REX in ED
Number of subjects: 15
Study 24595305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and protein intake
Number of subjects: 15
Study 24595305 — intervention group
Group type: COMPARATOR
Intervention: Energy deficit (ED)
Number of subjects: 15
Study 22434459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chrome on ultra-high-molecular-weight polyethylene
Number of subjects: 91
Study 22434459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chrome on highly cross-linked polyethylene
Number of subjects: 91
Study 22434459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic bearing
Number of subjects: 91
Study 22434459 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene (control)
Number of subjects: 91
Study 20146794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural nutritional support (energy and protein enriched diet, two additional servings of an oral nutritional supplement, vitamin D and calcium supplementation, consultations by a dietitian)
Number of subjects: 200
Study 20146794 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional care
Number of subjects: 200
Study 18045724 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 0
Study 18045724 — intervention group
Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 0
Study 16670110 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O with oxygen
Number of subjects: 228
Study 16670110 — intervention group
Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 228
Study 12788879 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 0.4 pmol/kg x min
Number of subjects: 12
Study 12788879 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 0.8 pmol/kg x min
Number of subjects: 12
Study 12788879 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 1.2 pmol/kg x min
Number of subjects: 12
Study 12788879 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (all doses)
Number of subjects: 12
Study 10976083 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise, taping, and education
Number of subjects: 81
Study 10976083 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise and education
Number of subjects: 81
Study 10976083 — intervention group
Group type: EXPERIMENTAL
Intervention: taping and education
Number of subjects: 81
Study 10976083 — intervention group
Group type: COMPARATOR
Intervention: education alone
Number of subjects: 81
Study 8972417 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cesarean section with continuous double layer closure of uterine incision and closure of visceral and parietal peritoneum
Number of subjects: 200
Study 8972417 — intervention group
Group type: COMPARATOR
Intervention: Modified technique with one layer closure of uterine incision and open visceral and parietal peritoneum
Number of subjects: 200
Study 8972417 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cesarean section
Number of subjects: 200
Study 8972417 — intervention group
Group type: COMPARATOR
Intervention: Modified technique
Number of subjects: 200
Study 8972417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 200
Study 1351796 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of loratadine
Number of subjects: 185
Study 1351796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 6083688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine + Dextran 70
Number of subjects: 107
Study 6083688 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 107
Study 6083688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine + Dextran 70 (hip replacement)
Number of subjects: 107
Study 6083688 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 107